Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

23.58 -0.41 (-1.71%)
Streaming Delayed Price Updated: 12:40 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 3/22
Via Investor Brand Network
Earnings Outlook For Harrow Health
Via Benzinga
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
From Harrow
Via Business Wire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow Health, Inc. (NASDAQ:HROW) Shareholder Notice: Investigation over Possible Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 03/08/2023 -- Harrow Health, Inc. is under investigation over potential securities laws in connection with certain financial statements. 
Via SBWire
Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
From Harrow
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
From Harrow
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
From The Rosen Law Firm, P.A.
Via Business Wire
Harrow Launches Next-Generation Compounded Atropine Formulations
From Harrow
Via Business Wire
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
From Harrow
Via Business Wire
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
From Harrow
Via Business Wire
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
From Harrow Health, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Secures Capital to Close Recently Announced Acquisition
From Harrow Health, Inc.
Via Business Wire
$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday following Fed’s rate decision, there were a few notable insider trades. 
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones
From Harrow Health, Inc.
Via Business Wire
Harrow Prices $25 Million Offering
From Harrow
Via Business Wire
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
From Harrow
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.